Cell remedy will get loads of consideration for its science: engineered immune cells that hunt tumors; remedies that may put terminal most cancers sufferers into remission; therapies that deal with ailments typical drugs has by no means been capable of contact.
What will get talked about much less is the half that occurs earlier than – the grinding, costly, steadily failing course of of really making these cells in portions massive sufficient to deal with folks.
Such is the issue ImmuneBridge was constructed round. And this week, after years of creating its method internally, the corporate stated it’s able to open it up.
The San Francisco biotech introduced a second seed spherical of $7.7 million USD, led by NFX – the enterprise agency behind Lyft, DoorDash, and Mammoth Biosciences, with over $1.5 billion USD underneath administration – alongside One Approach Ventures, M Ventures, Perception Companions, LongGame Ventures, T.Rx Capital, Healthspan Capital, Sand Hill Angels, and two unbiased buyers.
Whole seed funding now sits at practically $20 million USD. The elevate additionally marks the only largest funding LongGame Ventures has made up to now.
The capital will fund each ImmuneBridge’s inside pipeline and a brand new push to supply its platform to exterior companions – biotech startups and pharmaceutical firms that need to develop allogeneic immune therapies with out having to reinvent the manufacturing course of to do it.
Why manufacturing has been such a wall
Allogeneic cell remedy – constructing remedies from wholesome donor cells that may be saved and used throughout many sufferers reasonably than custom-made for every one – has lengthy been thought-about the mannequin that might make cell drugs genuinely scalable.
Autologous therapies, which require harvesting cells from the affected person, modifying them, and re-infusing them, can take over a month per therapy, and can’t realistically be mass-produced. Allogeneic approaches promise to alter the equation.
However the manufacturing actuality has been messier than the idea. Donor cells don’t carry out constantly, as their efficiency and growth potential varies considerably from individual to individual – making dependable large-scale manufacturing troublesome.
Past this, cells from completely different donors have differing propensities for growth – and due to this fact completely different yields – thus creating inconsistencies that may derail downstream processing.
Then, there’s the pluripotency downside: immune stem cells cultured in a lab are likely to lose the power to become the particular cell sorts wanted for remedy as they replicate. As soon as this occurs, the cells turn out to be far much less therapeutically helpful – and much costlier to work with. Most firms within the discipline can produce solely tens of doses from a single donor.
The business stays removed from a repeatable, standardized manufacturing course of which might help broader scientific and industrial deployment, with manufacturing fragmented, inconsistent and economically misaligned.
ImmuneBridge’s two-part repair
ImmuneBridge’s platform assaults each issues. First, the corporate makes use of a disease-specific donor screening system – the primary of its variety – that makes use of machine studying to establish which donors’ cells are more than likely to be efficient in opposition to a selected situation.
Reasonably than deciding on donors based mostly on basic well being markers and hoping for the most effective, the system narrows the sector on the earliest stage of improvement, curing waste and enhancing the chances of constructing one thing that truly works.
Second, the agency’s proprietary small molecule retains stem cells pluripotent even after repeated rounds of replication – that means that cells keep able to creating into no matter immune cell sort a given remedy requires, together with T cells for most cancers, NK cells for autoimmune problems, macrophages for liver fibrosis, neutrophils for extreme infections.
This twofold system permits the corporate to provide hundreds – and extra focused – therapeutic doses from a single donor, in comparison with tens most rivals can handle.
“Cell therapy has incredible potential to further revolutionize the treatment of cancer and a number of other diseases, but manufacturing has been a huge impediment,” stated Dr. Nina Horowitz, ImmuneBridge’s newly-appointed CEO.
“If you can’t make these therapies reliably and at scale, they won’t reach the people who need them.”
The folks behind it
Horowitz didn’t arrive at this work by way of a profession plan alone. At age eight, she was rushed to the ER with an ovarian teratoma – a uncommon tumor that may flip malignant. She recovered, nonetheless, and the expertise quietly formed her skilled ambitions.
After her PhD from Stanford, she joined ImmuneBridge as head of analysis, constructed the donor screening system, rose to Chief Scientific Officer, and was named CEO final yr.
Becoming a member of her as CTO is Rui Tostoes, who has spent his profession on a single query: “How do we make these therapies cheaper and reliable enough to help everyone – not just a handful of patients?” he stated. “At ImmuneBridge, we’re lastly aligning the biotechnology with the engineering, and we’re seeing true scalability consequently.
The market ready on the opposite aspect
The stakes for getting this proper are appreciable: the worldwide cell remedy market was valued at $8.88 billion USD in 2025, and is projected to succeed in $190 billion USD by 2034, as per a March 2026 research.
Manufacturing capability is constantly cited as one of many main development constraints. In different phrases, the one factor standing between the therapies being developed and the sufferers who may benefit from them.
“Manufacturing is the difference between hypotheticals and saving lives,” stated Semyon Dukach, founding accomplice at One Approach Ventures.
“ImmuneBridge is putting in place the systems that could make an entire class of therapies affordable and accessible.”
Conversely, Dr. Robert Lanfer, institute professor at MIR and govt chairman of T.Rx Capital, put it merely: “Every emerging field matures by strengthening its foundation. In cell therapy, that foundation is manufacturing.”
ImmuneBridge at present works with greater than a dozen companions throughout a number of cell sorts, and is concentrating on ten therapies within the clinic over the following ten years. They anticipate animal efficacy information later this yr, and have human trials penciled for 2028.
Featured picture: Courtesy of ImmuneBridge
Disclosure: This text mentions shoppers of an Espacio portfolio firm
